Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Work In Process (2016 - 2022)

Usana Health Sciences (USNA) has disclosed Work In Process for 12 consecutive years, with $8.0 million as the latest value for Q3 2022.

  • On a quarterly basis, Work In Process fell 7.44% to $8.0 million in Q3 2022 year-over-year; TTM through Jul 2022 was $8.0 million, a 7.44% decrease, with the full-year FY2022 number at $9.6 million, down 3.72% from a year prior.
  • Work In Process was $8.0 million for Q3 2022 at Usana Health Sciences, down from $9.7 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $14.5 million in Q4 2018 to a low of $8.0 million in Q3 2022.
  • A 5-year average of $10.7 million and a median of $10.0 million in 2018 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: skyrocketed 71.2% in 2018, then plummeted 39.12% in 2020.
  • Usana Health Sciences' Work In Process stood at $14.5 million in 2018, then decreased by 16.39% to $12.1 million in 2019, then dropped by 29.85% to $8.5 million in 2020, then rose by 22.14% to $10.4 million in 2021, then fell by 23.0% to $8.0 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Work In Process are $8.0 million (Q3 2022), $9.7 million (Q2 2022), and $9.6 million (Q1 2022).